Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLOMAX vs DOXAZOSIN MESYLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.
Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.
Treatment of signs and symptoms of benign prostatic hyperplasia (BPH),Off-label: adjunctive therapy for ureteral calculi expulsion
Hypertension,Benign prostatic hyperplasia (BPH),Off-label: Pheochromocytoma (preoperative management), Raynaud's phenomenon, ureteral stones
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.
Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.
Terminal elimination half-life is approximately 14-15 hours (range 6-20 hours) in healthy adults, allowing once-daily dosing.
Terminal elimination half-life is approximately 22 hours. This long half-life supports once-daily dosing for hypertension and benign prostatic hyperplasia.
Extensively metabolized in the liver via CYP3A4 and CYP2D6 enzymes.
Extensively metabolized in the liver via O-demethylation and hydroxylation, primarily by CYP3A4.
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <10% excreted unchanged in urine; fecal excretion accounts for ~76% of metabolites.
Approximately 63% of the dose is excreted in feces via biliary elimination, and about 9% is excreted unchanged in urine. The remainder is metabolized, with metabolites excreted in urine and feces.
94-99% bound primarily to alpha-1 acid glycoprotein, with high affinity.
Approximately 98-99% bound to plasma proteins, primarily albumin.
Approximately 16 L/kg (or 16 L for an average 70 kg patient), indicating extensive tissue distribution.
0.5-1.5 L/kg, indicating extensive distribution into tissues and extravascular spaces.
Oral bioavailability is approximately 90% (capsule) due to extensive absorption, with minimal first-pass metabolism.
Oral bioavailability is approximately 65% due to first-pass metabolism. Food does not significantly affect absorption.
No adjustment required for GFR ≥10 m L/min; insufficient data for GFR <10 m L/min, use with caution.
No dose adjustment needed for renal impairment. Doxazosin is minimally renally excreted.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution; consider starting at 0.4 mg once daily. Child-Pugh Class C: Contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh C). In mild-moderate impairment (Child-Pugh A or B), use with caution; consider starting at 1 mg once daily and titrate slowly.
Not approved for pediatric use; safety and efficacy not established.
Safety and effectiveness in pediatric patients have not been established. Not recommended for use in children.
Same dosing as adults; monitor for orthostatic hypotension and dizziness. Consider starting at 0.4 mg once daily.
Use cautiously due to increased risk of orthostatic hypotension, dizziness, and falls. Start at 1 mg once daily, titrate slowly. Monitor blood pressure carefully.
None.
None
Orthostatic hypotension and syncope, especially upon initiation or dose increase,Intraoperative floppy iris syndrome (IFIS) during cataract surgery,Priapism (rare),Hepatic impairment,Consideration of prostate cancer before initiating therapy
Orthostatic hypotension and syncope, especially with first dose ('first-dose effect'),Risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery,Hepatic impairment may decrease metabolism,Priapism (rare),Drowsiness/somnolence, caution with operating machinery
Hypersensitivity to tamsulosin hydrochloride or any component of the formulation,Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) in patients with moderate to severe hepatic impairment
Hypersensitivity to doxazosin or quinazolines,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of hypotension,Severe hepatic impairment
Grapefruit juice may increase tamsulosin levels; avoid concurrent intake. High-fat meals can decrease absorption; administer 30 minutes after the same meal daily.
Avoid grapefruit and grapefruit juice as they may increase drug levels. No other significant food interactions.
Tamsulosin is FDA Pregnancy Category B. Animal studies revealed no evidence of teratogenicity at doses up to 50 mg/kg/day in rats and 5 mg/kg/day in rabbits (approximately 50 and 30 times the human exposure). There are no adequate and well-controlled studies in pregnant women; use only if clearly needed. First trimester: no known increased risk of major malformations. Second/third trimester: no known specific fetal risks; however, alpha-blockers may cause hypotension in the mother, potentially affecting placental perfusion. No reports of teratogenic effects in humans.
FDA Pregnancy Category C. In animal studies, doxazosin showed no teratogenic effects in rats and rabbits at doses up to 20 and 8 mg/kg/day, respectively. There are no adequate and well-controlled studies in pregnant women. Potential fetal risks include possible hypotension and reduced placental perfusion, especially in the second and third trimesters. Use only if potential benefit justifies risk.
Tamsulosin is excreted in rat milk at concentrations 20-fold higher than maternal plasma. No human data exist; M/P ratio is not established. Due to potential for adverse effects (e.g., hypotension) in the nursing infant, breastfeeding is generally not recommended. Discontinue drug or bottle-feed, considering importance of therapy to mother.
Doxazosin is excreted in human milk. The milk-to-plasma ratio is not reported. Caution is advised; monitor infant for signs of hypotension. Consider alternative therapy in hypertensive mothers during breastfeeding.
No specific pharmacokinetic studies during pregnancy. Dose adjustments are not routinely recommended; however, hypotension risk may be increased due to pregnancy-related hemodynamic changes. Use the lowest effective dose and monitor for maternal hypotension to avoid fetal compromise.
No specific dose adjustments recommended for pregnancy. However, consider increased clearance and volume of distribution, especially in third trimester. Start with lowest effective dose (1 mg/day) and titrate based on blood pressure response. May require more frequent monitoring.
First-dose orthostatic hypotension is common; administer at bedtime. Avoid use in patients with history of cataract surgery due to intraoperative floppy iris syndrome (IFIS). Tamsulosin is not recommended for hypertension. Renal impairment does not require dose adjustment. Use caution with strong CYP3A4 inhibitors (e.g., ketoconazole) and PDE5 inhibitors (e.g., sildenafil) due to enhanced hypotensive effects.
First-dose syncope can occur; start with 1 mg at bedtime. Titrate slowly based on standing blood pressure. Monitor for orthostatic hypotension, especially in elderly. May cause intraoperative floppy iris syndrome (IFIS) during cataract surgery. Also used for benign prostatic hyperplasia (BPH) and hypertension.
Take this medication approximately 30 minutes after the same meal each day to maintain consistent absorption.,Avoid getting up too quickly from a sitting or lying position to minimize dizziness.,Inform your ophthalmologist about tamsulosin use before any cataract surgery due to risk of floppy iris syndrome.,Do not drive or operate heavy machinery until you know how this medication affects you.,If you miss a dose, skip it and take the next dose at the usual time; do not double the dose.
Take the first dose at bedtime to minimize dizziness.,Avoid sudden standing; rise slowly from sitting or lying positions.,May cause drowsiness; do not drive until you know how the medication affects you.,Avoid alcohol, as it can increase dizziness and drowsiness.,Inform your surgeon if you are taking this drug before cataract surgery.,Do not skip doses or discontinue abruptly; consult your doctor.
No interactions on record
"Rifampicin is a potent inducer of cytochrome P450 (CYP) 3A4, the primary enzyme responsible for the metabolism of doxazosin. Concurrent use significantly increases doxazosin clearance, reducing its plasma concentration and thereby diminishing its antihypertensive effect. This interaction may lead to loss of blood pressure control, necessitating dose adjustment or alternative therapy."
"Clemastine, a first-generation antihistamine, is primarily metabolized by hepatic cytochrome P450 enzymes, including CYP2D6 and CYP3A4. Doxazosin, an alpha-1 adrenergic receptor antagonist used for hypertension and benign prostatic hyperplasia, can inhibit these CYP isoenzymes, potentially leading to reduced clemastine clearance and elevated plasma concentrations. This may increase the risk of clemastine-related adverse effects such as sedation, anticholinergic toxicity (e.g., dry mouth, urinary retention), and paradoxical CNS stimulation, especially in elderly or renally impaired patients."
"Doxazosin, an alpha-1 adrenergic receptor antagonist, blocks vasoconstriction mediated by catecholamines, thereby opposing the vasopressor effects of ritodrine, a beta-2 adrenergic agonist that also possesses alpha-adrenergic activity. This pharmacodynamic antagonism can reduce the efficacy of ritodrine in achieving uterine relaxation and may lead to inadequate tocolysis or increased risk of maternal hypotension. Clinically, the combination may result in diminished tocolytic response and potential cardiovascular instability."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLOMAX vs DOXAZOSIN MESYLATE, answered by our medical review team.
FLOMAX is a Alpha-1 Blocker that works by Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.. DOXAZOSIN MESYLATE is a Alpha-1 Blocker that works by Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLOMAX and DOXAZOSIN MESYLATE depend on the specific clinical indication. These are both Alpha-1 Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLOMAX is: 0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.. The standard adult dose of DOXAZOSIN MESYLATE is: Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLOMAX and DOXAZOSIN MESYLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLOMAX is classified as Category C. Tamsulosin is FDA Pregnancy Category B. Animal studies revealed no evidence of teratogenicity at doses up to 50 mg/kg/day in rats and 5 mg/kg/day in rabbits (approximately 50 and 3. DOXAZOSIN MESYLATE is classified as Category A/B. FDA Pregnancy Category C. In animal studies, doxazosin showed no teratogenic effects in rats and rabbits at doses up to 20 and 8 mg/kg/day, respectively. There are no adequate and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.